December 10, 2012 10:03 AM | 28 seconds read |
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data fromSGN-CD33A, an antibody-drug conjugate (ADC) in development for the treatmentof acute myeloid leukemia (AML), at the 54^th American Society of Hematology(ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta,GA. SGN-CD33A is a novel CD33-directed ADC utilizing Seattle Genetics' nextgeneration technology. The CD33 antibody is attached to a highly potentcytotoxic agent called a pyrrolobenzodiazepine (PBD) dimer via a proprietarysite-specific conjugate technology to a monoclonal antibody with engineeredcysteines (EC-mAb). Seattle Genetics expects to advance SGN-CD33A into a phaseI clinical trial in 2013.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.